Immunohistochemical demonstration of the lysosome-associated glycoprotein CD68 (KP-1) in granular cell tumors and schwannomas

Kurtin, Paul J.; Bonin, Denis M.

doi:10.1016/0046-8177(94)90033-7

Cited by 108 publications

(70 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4,5,12,24 It is important to realise that granular cell tumours, although of Schwann cell origin, are not histologically identical to schwannomas, but rather constitute an entity of their own. Classically, schwannomas are encapsulated tumours of spindle-shaped cells that are typically arranged in a biphasic pattern composed of hypocellular Antoni B areas and cellular Antoni A areas containing Verocay bodies and showing pronounced nuclear palisading.…”

Section: Discussionmentioning

confidence: 99%

“…If a neurogenic lesion is found, FNAC can also differentiate a schwannoma from a granular cell tumour, with the help of immunocytochemical analysis. 4,5,12,24,28 Various decision-making algorithms have been described for the treatment of facial nerve schwannoma. In general, a 'watch and wait' attitude is adopted if there are no signs of facial palsy.…”

Section: Discussionmentioning

confidence: 99%

“…Since S-100 and cluster of differentiation 68 glycoprotein staining have become available, a Schwann cell derivation has been strongly suggested. [3][4][5][6][7][8] In 1983, May et al described the first granular cell tumour of the facial nerve, located in the mastoid. 9 Less than 20 cases of granular cell tumours of the parotid have previously been published, and this tumour is hardly ever mentioned in the differential diagnosis of parotid or facial nerve tumours.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A forgotten facial nerve tumour: granular cell tumour of the parotid and its implications for treatment

2010

View full text Add to dashboard Cite

We present a rare case of a facial nerve granular cell tumour in the right parotid gland, in a 10-year-old boy. A parotid or neurogenic tumour was suspected, based on magnetic resonance imaging. Intra-operatively, strong adhesions to surrounding structures were found, and a midfacial nerve branch had to be sacrificed for complete tumour removal. Recent reports verify that granular cell tumours arise from Schwann cells of peripheral nerve branches. The rarity of this tumour within the parotid gland, its origin from peripheral nerves, its sometimes misleading imaging characteristics, and its rare presentation with facial weakness and pain all have considerable implications on the surgical strategy and pre-operative counselling. Fine needle aspiration cytology may confirm the neurogenic origin of this lesion. When resecting the tumour, the surgeon must anticipate strong adherence to the facial nerve and be prepared to graft, or sacrifice, certain branches of this nerve.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A forgotten facial nerve tumour: granular cell tumour of the parotid and its implications for treatment

2010

View full text Add to dashboard Cite

show abstract

“…The origin of granular cell tumor is uncertain. Based on the evidence that monoclonal antibody KP1 which recognises the lysosome associated glycoprotein CD68 reacts positively with Schwannomas and granular cell tumors, it is believed that these tumors arise from schwan cells (8) . Granular cell tumors stain cytoplasmically for S100 protein and are closely associated with nerves .They often present near distal nerve trunks (9) .…”

Section: Discussionmentioning

confidence: 99%

Atypical Granular Cell Tumor with Intranuclear Inclusions: A Case Report

P¹

2016

jmscr

View full text Add to dashboard Cite

show abstract

“…2,3 The purpose of this study was to explore whether the allorestricted strategy can be used to identify CTL epitopes in CD68. CD68, a differentiation marker of haematopoietic cells of the monocyte and macrophage lineage, was found to be produced at elevated levels in a number of human tumours including acute myeloid leukaemia, 4 shwannomas, granular cell tumours 5 and hystiocytomas. 6 We have focused on the identification of CTL epitopes presented by HLA-A2 because this class I allele is present in nearly 50% of Caucasian individuals.…”

Section: Introductionmentioning

confidence: 99%

The CD68 protein as a potential target for leukaemia-reactive CTL

Sadovnikova

Паровичникова

et al. 2002

Leukemia

View full text Add to dashboard Cite

CD68, a haematopoietic differentiation marker of the monocyte-macrophage lineage, is expressed in various human malignancies including chronic and acute myeloid leukaemia (AML). While the majority of normal CD34 + cells are negative for CD68 expression, CD34 + cells from AML patients produce elevated amounts of this protein. The purpose of this study was to identify CTL epitopes in the human CD68 protein. Mouse CD68 was also analysed to search for epitopes that could be used in murine tumor model. Peptides binding to murine H2 b class I molecules were identified and used to stimulate CTL responses from allogeneic donor mice to avoid immunological tolerance. High avidity CTL clones specific for three different peptide epitopes did not kill CD68-expressing murine target cells, indicating that endogenous antigen processing failed to produce sufficient amounts of these peptides. In contrast, allorestricted human CTL specific for an HLA-A2-binding peptide of CD68 recognised not only picomolar concentrations of peptide, but also displayed low levels of killing against HLA-A2-positive K562 and THP-1 leukemia cell lines and blast cells from AML patients. These data suggest that human leukaemia cells express limited amounts of CD68-derived peptides, and that high avidity CTL capable of recognising sub-picomolar concentrations of peptides are required for efficient killing of leukaemia cells. Leukemia (2002) IntroductionThe success of tumour immunotherapy is largely dependent on the choice of target antigen. Tumour-associated antigens, that are targeted by various immunotherapy strategies fall into three categories: viral antigens, products of mutated genes and normal cellular proteins. The latter category, which comprises differentiation antigens, has been extensively exploited for the treatment of solid tumours, such as melanoma and prostate cancer. 1 Self-tolerance to differentiation antigens expressed in non-haematopoietic cells is probably not absolute, providing an explanation for the detection of CTL against these antigens in tumour patients. The use of haemopoietic differentiation antigens, however attractive it may appear for the purposes of targeting cellular immune responses against leukaemic blast cells, is limited by potent tolerogenic effects of haemopoietic cells. Hence, it is likely that autologous T cells specific for haemopoietic differentiation antigens have been deleted in the thymus or rendered unresponsive by peripheral tolerance mechanisms.In the past few years, we have developed a strategy to circumvent tolerance to self proteins. 2 The allo-restricted strategy is based on the observation that T cell tolerance is self-MHC restricted. Hence, T cells from A2-negative donor individuals can mount CTL responses against epitopes from self-proteins presented by A2 class I molecules. Using this strategy, we have previously identified CTL epitopes in the self-proteins mdm2 and cyclin D1, and shown that the CTL selectively killed tumour cells expressing large quantities of these proteins but not normal ce...

show abstract

Immunohistochemical demonstration of the lysosome-associated glycoprotein CD68 (KP-1) in granular cell tumors and schwannomas

Cited by 108 publications

References 31 publications

A forgotten facial nerve tumour: granular cell tumour of the parotid and its implications for treatment

A forgotten facial nerve tumour: granular cell tumour of the parotid and its implications for treatment

Atypical Granular Cell Tumor with Intranuclear Inclusions: A Case Report

The CD68 protein as a potential target for leukaemia-reactive CTL

Contact Info

Product

Resources

About